Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson’s disease
Tau has shown to be associated with neurodegenerative diseases. In this exploratory study, we investigated the utility of blood-based biomarkers measuring Tau-C, Tau-A, and C1M in Parkinson’s disease (PD) to explore their potential as diagnostic biomarkers in two independent cohorts (TAU-C and TAU-A...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1566228/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Tau has shown to be associated with neurodegenerative diseases. In this exploratory study, we investigated the utility of blood-based biomarkers measuring Tau-C, Tau-A, and C1M in Parkinson’s disease (PD) to explore their potential as diagnostic biomarkers in two independent cohorts (TAU-C and TAU-A). We found them to discriminate between healthy donors and PD individuals (all p < 0.001), with Tau-C showing the best diagnostic discrepancy (AUROC = 0.97). Therefore, Tau-C, Tau-A, and C1M may be biomarkers for PD diagnosis. |
|---|---|
| ISSN: | 1664-2295 |